REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
Status:
Completed
Trial end date:
2010-07-06
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the anti-tumor activity of REVLIMID®
(lenalidomide), administered as a single agent, in patients with distantly metastatic thyroid
carcinomas which are unresponsive to systemic radioiodine, in terms of tumor response and
response duration.